Medical Device Clinical Monitoring Services

The Sponsor's Obligation

Monitoring Is a Sponsor Responsibility

FDA is direct about who is on the hook. Under 21 CFR 812.43(d), a sponsor "shall select monitors qualified by training and experience to monitor the investigational study." Under 21 CFR 812.46(a), a sponsor who discovers that an investigator is not complying with the signed agreement, the investigational plan, or applicable requirements "shall promptly either secure compliance, or discontinue shipments of the device to the investigator and terminate the investigator's participation in the investigation."

Those two sentences define the job. Monitoring exists to catch protocol deviations, consent problems, data errors, and safety reporting gaps while they can still be fixed, and to give the sponsor the standing to act when a site will not comply. A monitor can be a sponsor employee or a qualified person the sponsor contracts to perform the role. We perform that role for device sponsors, and for foreign manufacturers we perform it as part of serving as U.S. sponsor of record.

The Plan

A Monitoring Plan Built for Your Study

Good monitoring starts with a written clinical monitoring plan that says who monitors, how often, at what level of detail, and against which risks. A single-site feasibility study and a multi-site pivotal study do not need the same plan, and treating them the same either wastes money or misses problems.

We write the monitoring plan around the actual risk profile of your device and protocol: the critical data points, the endpoints, the consent process, device accountability, and safety reporting. We define what is verified on site, what can be reviewed remotely or centrally, and what triggers an unscheduled visit. The plan becomes part of the trial master file and gives FDA a clear account of how the study was overseen.

The Visits

Qualification, Initiation, Interim, and Close-Out

Monitoring happens through a defined sequence of visits, and each one has a different job.

Site qualification confirms, before a site is selected, that it has the patient population, the staff, the facilities, and the research experience to deliver. A qualification visit can end with a site not being selected, which is the point.

Site initiation happens after a site is selected but before it enrolls anyone. This is where we train the investigator and coordinators on the protocol, the case report forms, device handling, safety reporting, and their obligations, and confirm the site is ready to activate.

Interim monitoring runs throughout enrollment and follow-up. These are the recurring visits where we verify eligibility and consent, check source data against the case report forms, confirm device accountability, review safety reporting, and work down the query list. This is where most protocol drift is caught and corrected.

Close-out reconciles everything at the end: outstanding queries resolved, device accountability complete, essential documents filed, and the site prepared for archiving.

Every visit produces a monitoring visit report, which is itself a regulated record an FDA inspector can review later. We write them to that standard.

Securing Compliance

When a Site Is Not Complying

Finding a compliance problem is only half the obligation. The regulation requires the sponsor to act on it. When monitoring surfaces non-compliance, we document it, escalate it, and work with the site to secure compliance. If the site cannot or will not comply, the sponsor's path under 812.46(a) is to discontinue device shipments and terminate that investigator's participation. We manage that process, including the FDA and IRB notifications that follow, so the rest of the study is protected.

We also handle the safety side of monitoring. When an unanticipated adverse device effect is reported, the sponsor must evaluate it and report the results to FDA, all reviewing IRBs, and all participating investigators within 10 working days of first receiving notice. We run that evaluation and make those notifications on time.